18 beta-glycyrrhetinic acid regulates mitochondrial ribosomal protein L35-associated apoptosis signaling pathways to inhibit proliferation of gastric carcinoma cells
Ling Yuan,Yi Yang,Xia Li,Xin Zhou,Yu-Hua Du,Wen-Jing Liu,Lei Zhang,Lei Yu,Ting-Ting Ma,Jia-Xin Li,Yan Chen,Yi Nan
DOI: https://doi.org/10.3748/wjg.v28.i22.2437
IF: 5.374
2022-01-01
World Journal of Gastroenterology
Abstract:BACKGROUND Gastric carcinoma (GC) is a common gastrointestinal malignancy worldwide. Based on the cancer-related mortality, the current prevention and treatment strategies for GC still show poor clinical results. Therefore, it is important to find effective drug treatment targets. AIM To explore the mechanism by which 18 beta-glycyrrhetinic acid (18 beta-GRA) regulates mitochondrial ribosomal protein L35 (MRPL35) related signal proteins to inhibit the proliferation of GC cells. METHODS Cell counting kit-8 assay was used to detect the effects of 18 beta-GRA on the survival rate of human normal gastric mucosal cell line GES-1 and the proliferation of GC cell lines MGC80-3 and BGC-823. The apoptosis and cell cycle were assessed by flow cytometry. Cell invasion and migration were evaluated by Transwell assay, and cell scratch test was used to detect cell migration. Furthermore, a tumor model was established by hypodermic injection of 2.5 x 106 BGC-823 cells at the selected positions of BALB/c nude mice to determine the effect of 18 beta-GRA on GC cell proliferation, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect MRPL35 expression in the engrafted tumors in mice. We used the term tandem mass tag (TMT) labeling combined with liquid chromatography-tandem mass spectrometry to screen for differentially expressed proteins (DEPs) extracted from GC cells and control cells after 18 beta-GRA intervention. A detailed bioinformatics analysis of these DEPs was performed, including Gene Ontology annotation and enrichment analysis, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis, and so on. Moreover, STRING database (https://string-db.org/) was used to predict proteinprotein interaction (PPI) relationships and Western blot was used to detect the expression of proteins of interest in GC cells. RESULTS The results indicated that 18 ss-GRA could inhibit the proliferation of GC cells in a dose- and timedependent manner. It could induce GC cell apoptosis and arrest the cell cycle at G0/G1 phase. The proportion of cells arrested at S phase decreased with the increase of 18-GRA dose, and the migration and invasiveness of GC cells were inhibited. The results of animal experiments showed that 18 beta-GRA could inhibit tumor formation in BALB/c nude mice, and qRT-PCR results showed that MRPL35 expression level was significantly reduced in the engrafted tumors in mice. Using TMT technology, 609 DEPs, among which 335 were up-regulated and 274 were down-regulated, were identified in 18 beta-GRA intervention compared with control. We found that the intervention of 18 beta-GRA in GC cells involved many important biological processes and signaling pathways, such as cellular processes, biological regulation, and TP53 signaling pathway. Notably, after the drug intervention, MRPL35 expression was significantly down- regulated (P = 0.000247), TP53 expression was up-regulated (P = 0.02676), and BCL2L1 was down- regulated (P = 0.01699). Combined with the Retrieval of Interacting Genes/Proteins database, we analyzed the relationship between MRPL35, TP53, and BCL2L1 signaling proteins, and we found that COPS5, BAX, and BAD proteins can form a PPI network with MRPL35, TP53, and BCL2L1. Western blot analysis confirmed the intervention effect of 18 beta-GRA on GC cells, MRPL35, TP53, and BCL2L1 showed dose-dependent up/down- regulation, and the expression of COPS5, BAX, and BAD also increased/decreased with the change of 18 beta-GRA concentration. CONCLUSION 18 beta-GRA can inhibit the proliferation of GC cells by regulating MRPL35, COPS5, TP53, BCL2L1, BAX, and BAD.